NASDAQ:NCRA Nocera (NCRA) Stock Price, News & Analysis $0.98 -0.05 (-4.85%) As of 09:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsSEC FilingsShort InterestTrendsBuy This Stock About Nocera Stock (NASDAQ:NCRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nocera alerts:Sign Up Key Stats Today's Range$1.03▼$1.0550-Day Range$0.81▼$1.1752-Week Range$0.70▼$2.09Volume6,003 shsAverage Volume78,951 shsMarket Capitalization$14.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Nocera (NASDAQ: NCRA) is a clinical-stage biotechnology company focused on the development of novel RNA-based therapeutics for the treatment of rare and debilitating neurological disorders. Leveraging proprietary messenger RNA (mRNA) platforms and lipid nanoparticle delivery systems, Nocera is pioneering targeted therapeutic approaches aimed at addressing diseases with high unmet medical need. The company’s research and development pipeline encompasses several preclinical and early-stage clinical programs, including treatments for inherited neurodegenerative conditions and central nervous system injuries. Founded in 2016 as a spin-out from a leading academic research institution, Nocera has grown its capabilities through strategic partnerships with major academic medical centers and contract research organizations. Headquartered in Boston, Massachusetts, the company maintains additional research facilities in Germany and Singapore to support global clinical trial operations and regulatory activities. Nocera’s cross-functional team includes experts in molecular biology, pharmacology, translational medicine and regulatory affairs, all working collaboratively to advance its therapeutic candidates toward proof-of-concept and registration stages. Under the leadership of Chief Executive Officer Dr. Sarah Kim, who brings more than two decades of experience in pharmaceutical development and biotechnology, Nocera has solidified its commitment to scientific innovation and patient-centric drug development. Dr. Kim is supported by Chief Scientific Officer Dr. Mark Rodriguez, a recognized authority in RNA therapeutics, and a management team with deep expertise in manufacturing scale-up, clinical development and commercialization strategies. Together, they are guiding Nocera’s vision of transforming promising laboratory discoveries into safe and effective treatments for patients worldwide.AI Generated. May Contain Errors. Read More Receive NCRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nocera and its competitors with MarketBeat's FREE daily newsletter. Email Address NCRA Stock News HeadlinesNocera, Inc. Makes Strategic Investment in Tachyonext Inc. to Enter U.S. E-Commerce Market and Expand Consumer Tech Portfolio - FinanzNachrichten.deJune 26, 2025 | finanznachrichten.deNocera, Inc. Makes Strategic Investment in Tachyonext Inc. to Enter U.S. E-Commerce Market and Expand Consumer Tech Portfolio - MorningstarJune 26, 2025 | morningstar.comMTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tied to President Trump's Executive Order #14196 could not only rescue Social Security... But also boost benefits by up to 400%, according to legendary investor Louis Navellier.July 10 at 2:00 AM | InvestorPlace (Ad)Nocera faces Nasdaq compliance issue over late annual reportApril 29, 2025 | investing.comNocera, Inc. Receives Nasdaq Notice Due to Delay in Filing 2024 Annual Report | NCRA Stock NewsApril 28, 2025 | gurufocus.comNocera Second Quarter 2024 Earnings: US$0.026 loss per share (vs US$0.032 loss in 2Q 2023)August 18, 2024 | finance.yahoo.comNocera, Inc. (NCRA) Stock Price, News, Quote & History - Yahoo FinanceMay 16, 2024 | finance.yahoo.comLifevantage and Safety Shot among Consumer Staples moversApril 22, 2024 | msn.comSee More Headlines NCRA Stock Analysis - Frequently Asked Questions How have NCRA shares performed this year? Nocera's stock was trading at $0.8463 on January 1st, 2025. Since then, NCRA stock has increased by 15.8% and is now trading at $0.98. How were Nocera's earnings last quarter? Nocera, Inc. (NASDAQ:NCRA) released its quarterly earnings results on Thursday, May, 15th. The company reported ($0.02) earnings per share for the quarter. The company earned $4.53 million during the quarter. Nocera had a negative trailing twelve-month return on equity of 47.60% and a negative net margin of 12.70%. When did Nocera IPO? Nocera (NCRA) raised $9 million in an initial public offering (IPO) on Thursday, August 11th 2022. The company issued 2,400,000 shares at $3.50-$4.00 per share. Spartan Capital and Revere Securities acted as the underwriters for the IPO. How do I buy shares of Nocera? Shares of NCRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nocera own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nocera investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings5/15/2025Today7/09/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorConsumer Staples Industry FOOD - MISC/DIVERSIFIED Sub-IndustryAgriculture Current SymbolNASDAQ:NCRA CIK1756180 Webwww.nocera.company Phone886910163358FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.35 million Net Margins-12.70% Pretax Margin-14.15% Return on Equity-47.60% Return on Assets-35.67% Debt Debt-to-Equity RatioN/A Current Ratio1.81 Quick Ratio1.79 Sales & Book Value Annual Sales$17.01 million Price / Sales0.88 Cash FlowN/A Price / Cash FlowN/A Book Value$0.30 per share Price / Book3.47Miscellaneous Outstanding Shares14,370,000Free Float13,606,000Market Cap$14.94 million OptionableNot Optionable Beta1.21 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:NCRA) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nocera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nocera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.